Navigation Links
Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint

vantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, please visit www.sybd.com.

Safe Harbor Statement The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking information made on the Company's behalf. All statements, other than statements of historical facts which address the Company's expectations of sources of capital or which express the Company's expectation for the future with respect to financial performance or operating strategies, can be identified as forward-looking statements. Such statements made by the Company are based on knowledge of the environment in which it operates, but because of the factors previously listed, as well as other factors beyond the control of the Company, actual results may differ materially from the expectations expressed in the forward-looking statements.

Contact

Synthetic Blood International Inc.
Joan Mahan, 800-809-6054
or
Investor Contacts:
Lippert/Heilshorn & Associates, Inc.
Jody Cain, jcain@lhai.com
Brandi Floberg, bfloberg@lhai.com
310-691-7100


'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:10/8/2008)...nce, Oct. 8 /- Vical Incorporated (Na...l data and new nonclinical data,demonstrating that...y,applicable in DNA- and protein-based infectious .... Alain P. Rolland, Pharm.D., Ph.D., Vical,s,Senio...ent the data today,Wednesday, October 8, at the W...
(Date:10/7/2008)...ch., Oct. 7 /- McLaren Health Care an...ome of the world,s leading medical,minds to share ...t and,gastrointestinal cancer treatments. The Octo...s organized by McLaren,s Sukamal Saha, M.D., an,aw...inel node mapping for,colorectal cancer has gained...
(Date:10/7/2008)...f FLEXX Trial Presented at the Osteoarthritis Rese... PARSIPPANY, N.J., Oct. 7 /- Ferring ...om the FLEXX Trial of Osteoarthritis of the,Knee, ...a highly pure,non-avian high molecular weight form...perior to intra-articular saline (IA-saline) for t...
(Date:10/7/2008)...a., Oct. 7 /- CEL-SCI Corpo...ntered into a Material Transfer,Agreement (MTA) wi...er,(NIHCC) and the laboratory of Dr. Francesco M. ...s of changes to the tumor microenvironment,caused ...is the Chief of,the Infectious Disease and Immunog...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3ORENCIA 28R 29 28abatacept 29 Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review 58 1ORENCIA 28R 29 28abatacept 29 Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review 58 2ORENCIA 28R 29 28abatacept 29 Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review 58 3ORENCIA 28R 29 28abatacept 29 Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review 58 4Callisto Reports on Second Quarter 2007 Milestones 54 1Callisto Reports on Second Quarter 2007 Milestones 54 2Callisto Reports on Second Quarter 2007 Milestones 54 3Callisto Reports on Second Quarter 2007 Milestones 54 4WallSt net 28www wallst net 29 Updates the Investment Community Through an All New Interview With RegeneRx Biopharmaceuticals CEO 50 1WallSt net 28www wallst net 29 Updates the Investment Community Through an All New Interview With RegeneRx Biopharmaceuticals CEO 50 2Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine 46 1Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine 46 2Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine 46 3Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine 46 4
...Than for Asthma,Rheumatoid Arthritis and Migraine... three out of,four ulcerative colitis (UC) suffere...vey say not feeling well has become a normal part,...ve when it comes,to their relationship with a spou...t) and their emotional state (82 percent). , UC pa...
...Inovio Biomedical,Corporation (AMEX:INO), focused ...rs and infectious diseases and a novel,alternative...today,that partners of the company will present ne... plasmid-based immunotherapies using,Inovio,s elec...national Conference on DNA Vaccines in Malaga, Spa...
Other Medicine Technology:Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 2Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 3Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 4Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 5Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 6Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 7Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 8Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 9Inovio Biomedical's Partners to Present New Data from Two Cancer,Immunotherapy Clinical Trials 2Inovio Biomedical's Partners to Present New Data from Two Cancer,Immunotherapy Clinical Trials 3Inovio Biomedical's Partners to Present New Data from Two Cancer,Immunotherapy Clinical Trials 4
(Date:10/8/2008)... Juva Skin & Laser Center is ...etic skin treatments in New York City. The facilit...re:fine, one of the latest skin resurfacing treatm...nvasive laser equipment. , ...etic surgery and laser treatment industry is in th...
(Date:10/7/2008)...MBUS, Ohio, Oct. 7 /PRNewswire-USNewswire/ -- The ...ity (ONA-PCE) announced today its,final round of e...on,including:, Ohio Senate:, SD 26 Karen Gillmo... 23 Cheryl Grossman (R) Grove City;, HD 28 Connie...g (R) Cincinnati, "These ONA-endorsed candidates ...
(Date:10/7/2008)...out of bed sooner helped quality of life after dis...(HealthDay News) -- The best medicine for intensiv... of bed and moving as soon as they,re able, a new ...t data, Johns Hopkins University School of Medicin...ep sedation and bed rest may cause unnecessary and...
(Date:10/7/2008)...gists at the Moores Cancer Center at the Universit...hoping to stave off the relentless march of advanc...ind of cancer vaccine. While many vaccines attempt...r, the new vaccine, Lucanix, is genetically engine... immune system-suppressing activities. , The fir...
Breaking Medicine News(10 mins):Health News:Upscale New York City Skin Care Center Juva Offering FDA Approved Fraxel re:fine System 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Early Mobility Best for ICU Patients 2Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2
...ectin can predict whether a pregnant woman is at r...sk for pre-term births are women with previous pre...egnancy, and those who suffer from diabetes and/or...whether a woman will go into premature labor is th...
...ogesterone levels may be helpful in deciding which...ical signs are at low risk of ectopic pregnancy, a...nals of Emergency Medicine. They measured proges...ster patients who presented to an emergency depart...
...ity research team has discovered a new family of g..., shedding new light on the abnormalities that giv...'s lymphoma - as well as lymphoma, leukemia, prost...t cancer. Characterized by rapidly growing abdom...
...hildren with autism. Antibiotcs seem to treat or p...ne in every 150 children is affected by autism. Cu...ondition. Researchers from Rush-Presbyterian-St. L...ubset of patients with autism who experience a col...
Other Medicine News:
The grasper wires are constructed of stainless steel Delta Wire. The revolutionary triangular shape of Delta Wire creates a three-prong grasper with the largest possible wire mass. The superior mass
Micro-throw grasping technology allows the grasper to open wider in a shorter length and permits close approximation to the stone. The Unidex handle facilitates easy, ergonomic one-handed operation.
Fulgurating Electrode, 2 F
...roscope is used for percutaneous and transurethral...large 6.4 Fr (2.1 mm) working channel accommodates...utic applications. The flexible shaft, small outer...vide fast, less traumatic access and increased pat...
Medicine Products: